Delivery Order SPE2DB20D3101-SPE2DB25FRSE6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,657.21 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pen injectables on July 21, 2025, with completion scheduled for July 22, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a single delivery of the pharmaceutical product to support federal medical supply requirements. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as the performing location for...
- The Defense Logistics Agency awarded a delivery order valued at $5,400.47 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The pharmaceutical product will be performed at the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $14,934.34 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $18,415.47 delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and represents a direct delivery of pharmaceutical products to support federal healthcare operations. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at approximately $15.5K to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pen injections on August 4, 2025, with completion expected by August 5, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- The Defense Logistics Agency awarded a delivery order valued at $12,807.68 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens (2 mL). This competitive award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a firm fixed-price delivery order with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfills this order as part of its extensive federal...
- The Defense Logistics Agency awarded a delivery order valued at $7,945.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on August 11, 2025, with a completion date of August 12, 2025. This firm fixed-price, competitively awarded delivery order represents a single transaction under AmerisourceBergen's larger pharmaceutical supply framework. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency awarded a delivery order valued at $47,262.06 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 mL pens. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 12, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the vendor's demonstrated capability to compete openly for...
- The Defense Logistics Agency (DLA) awarded a $5,128.38 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml) pharmaceutical supply, with an ultimate completion date of July 31, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed price pricing and is classified as a child contract, indicating it derives from a larger contract vehicle. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a $28,068.76 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pens on July 22, 2025, with an ultimate completion date of July 23, 2025. This non-set-aside, firm fixed price contract represents a single delivery order under the company's existing indefinite delivery vehicle with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRSE6Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,150.42 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen (2 ml) pharmaceutical supplies. This is a firm fixed price, competitively awarded delivery order with no set-aside designation, with an ultimate completion date of August 12, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform the contract at its corporate office location. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. That prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling the company to supply pharmaceutical products and medical supplies to support military healthcare programs worldwide, including critical medical commodities such as specialty medications, brand-name and generic drugs, vaccines, and medical supplies across multiple therapeutic domains. The DLA intends to establish Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen to serve customers including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 8/11/25 |